Your session is about to expire
← Back to Search
CagriSema, Semaglutide, and Cagrilintide for Type 2 Diabetes(REIMAGINE 2 Trial)
REIMAGINE 2 Trial Summary
This trial will explore if CagriSema, a weekly medicine combining two existing medications, can help lower blood sugar and body weight in people with type 2 diabetes.
- Type 2 Diabetes
REIMAGINE 2 Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
REIMAGINE 2 Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
REIMAGINE 2 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any adverse effects associated with administering CagriSema 2.4 mg/2.4 mg to patients?
"The safety of CagriSema 2.4 mg/2.4 mg can be assessed at a 3 due to the Phase 3 trial, signifying that there is sufficient evidence for efficacy and numerous rounds of data supporting its security."
How many venues has this experiment been conducted in?
"Patient recruitment has spread to 289 different sites, among them Pelham, Phoenix and Little Rock. It may be advantageous for potential participants to select the closest site in order to curtail their commutation demands."
Is this experiment available for enrollment at present?
"As per clinicaltrials.gov, this trial is not admitting new participants. It was first uploaded on September 27th 2023 and last updated the day before that date. Although no longer enrolling patients, there are 1464 other studies with open recruitment at present."
What are the expected results of this medical experiment?
"The primary focus of this study is to compare the relative change in body weight from baseline (week 0) to end-of-treatment (week 68) between CagriSema 2.4 mg/2.4 mg and semaglutide 2.4 mg/2.4 mg, as well as CagriSema 1.0 mg/1.0 mg and semaglutide 1.0mg/1.0mg; both assessments being made via percentage measurements.. Secondary objectives include comparing the relative change in body weight for CagriSema 2.4mg/2.. 4 versus"
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends